Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests, has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients.
As part of the tie-up, Biocept will offer the association an array of cancer-detection tools such as biomarker tests as well as a liquid biopsy panel to help its physicians cater to their patients.
“Now, more people in California will have access to our Target Selector liquid biopsy testing services, which can help physicians identify actionable biomarkers in patients diagnosed with cancer and design personalized treatment programs in order to improve outcomes,” said Michael Nall, Biocept’s CEO.
Headquartered in San Diego, Biocept is a diagnostics company which offers assays to detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma. Its flagship Target Selector technology platform collects and analyzes molecular markers linked to tumors in circulating tumor cells as well as plasma to identify cancer mutations.